5116S-11: S0820 colon

SWOG 0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III

Type of Study
Cancer (Oncology) - Colon
Location
Swedish Cancer Institute
Short Description

Purpose: The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer

Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • History of Stage 0-III colon cancer with primary resection 1 year previously
  • Patients with rectosigmoid cancers eligible if no RT administered
  • One-year post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence of disease
  • Low risk or moderate risk of cardiovascular events
  • At least 30 days from completion of prior adjuvant chemotherapy
  • Able to swallow oral medications
  • No history of colon resection > 40 cm
  • No mid-low rectal cancer
  • No recurrent or metastatic disease
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org